WebNov 8, 2024 · November 8, 2024 Christopher A. Herr Dan Chevallard Michael White Oxford Finance Silicon Valley Bank Viracta Therapeutics Ian Koplin WebMay 7, 2024 · Dan Chevallard - VP of Finance & Accounting Analysts Matthew Luchini - BMO Capital Alan Carr - Needham Madhu Kumar - Chardan Yanan Zhu - Wells Fargo Securities Operator Good afternoon, ladies and...
Viracta Therapeutics Announces Closing of Merger with Sunesis ...
WebApr 27, 2024 · And after the drinks were covered, Dan Chevallard, COO and Chief Financial Officer of Viracta, spoke about his journey with Viracta, a precision oncology company targeting virus-associated malignancies such as EBV+ cancers. Not only science was covered, but ideas about how to fundraise too, another incredibly important part of a … WebNov 8, 2024 · “This expanded credit facility increases our financial strength and provides the company with significant strategic and operational flexibility by securing access to a non-dilutive and immediately available financing option that carries an attractive single-digit cost of capital,” Dan Chevallard, COO and CFO at Viracta Therapeutics, said. forme bnc
Tinexta heeft meer dan 41.000 eigen gewone aandelen ingekocht
WebMar 4, 2024 · In addition to the appointments of Ms. Madsen and Drs. Rubino and Simon, Viracta also announced the following management promotions, which are significant in … WebAug 1, 2024 · Viracta Therapeutics, Inc. announced that it has appointed Dan Chevallard as Chief Financial Officer and Xiaohu Deng, Ph.D. as Senior Vice President of Product … WebNov 8, 2024 · Dan Chevallard - Chief Financial Officer, Principal Financial and Accounting Officer Analysts Matthew Luchini - BMO Capital Joseph Thome - Cowen and Company Nick Abbott - Wells Fargo Operator... forme blucher plain toe